| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal. |
| 掲載誌名 | 正式名：Research and practice in thrombosis and haemostasis 略 称：Res Pract Thromb Haemost ISSNコード：24750379/24750379 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 8(2),pp.102363 |
| 著者・共著者 | Cihan Ay, Olga Benitez-Hidalgo, Gillian Gidley, Maria Elisa Mancuso, Davide Matino, Azusa Nagao, Laszlo Nemes, John Waller, Johannes Oldenburg |
| 発行年月 | 2024/02 |
| 概要 | BACKGROUND:Joint damage affects the quality of life of persons with hemophilia A. The long-term safety and efficacy of turoctocog alfa pegol (N8-GP) prophylaxis in persons with hemophilia A has been investigated in pivotal phase 3 trials in children, adolescents, and adults (pathfinder program). However, there is a lack of data on joint health in adult persons with hemophilia A treated with N8-GP.OBJECTIVES:To describe the design of the ongoing pathfinderReal study investigating the joint health status in adult persons with hemophilia A after switching to N8-GP.METHODS:pathfinderReal is a multicountry, noninterventional, single-arm study (NCT05621746) of joint health in adult (≥18 years) male persons with hemophilia A who have switched to N8-GP. Patients enrolled in other interventional studies and those who have previously terminated N8-GP treatment will be excluded. Approximately 124 adults with hemophilia A will be enrolled and followed up for a maximum of 24 months. Data from routine clinical assessments of patients' joint health will be collected. The primary endpoint is change in Hemophilia Joint Health Score (defined as a change in total score of ≤2) from initiation of N8-GP treatment until the end of the study. Secondary endpoints include number of bleeding episodes, number and resolution of target joints, patient-reported outcomes of problem joint score, pain score, and change in physical function levels. An exploratory endpoint is included to measure the number of patients achieving improved Hemophilia Joint Health Score from the initiation of N8-GP until the end of the study.CONCLUSION:The pathfinderReal study will provide insights regarding the impact of N8-GP on joint health in persons with hemophilia A in a real-world setting. |
| DOI | 10.1016/j.rpth.2024.102363 |
| PMID | 38572481 |